MQS Management LLC Makes New Investment in Kenvue Inc. $KVUE

MQS Management LLC purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) in the second quarter, HoldingsChannel reports. The institutional investor purchased 14,396 shares of the company’s stock, valued at approximately $301,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pittenger & Anderson Inc. bought a new position in Kenvue during the first quarter worth about $30,000. TruNorth Capital Management LLC bought a new position in Kenvue during the first quarter worth about $36,000. Truvestments Capital LLC bought a new position in Kenvue during the first quarter worth about $37,000. Trust Co. of Vermont lifted its stake in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after purchasing an additional 1,150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock opened at $15.04 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The firm has a market cap of $28.87 billion, a P/E ratio of 20.33, a P/E/G ratio of 2.16 and a beta of 0.72. The firm has a 50 day simple moving average of $17.78 and a 200 day simple moving average of $20.74. Kenvue Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter last year, the business posted $0.32 earnings per share. Kenvue’s revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a yield of 5.5%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Analyst Ratings Changes

A number of brokerages have commented on KVUE. Barclays cut their price target on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 1st. Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Redburn Partners set a $22.00 target price on shares of Kenvue in a research note on Friday, September 26th. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Finally, JPMorgan Chase & Co. cut their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.90.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.